The potential interplay between Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) infection and treatment with immune-checkpoint inhibitors (ICI) of cancer patients is presently unknown. 1 In this context, the increasing spreading of the coronavirus (COVID-19) pandemic does not help; in fact, major health resources are being redirected to counteract the pandemic 2 , raising the concrete risk to hamper cancer care significantly 3 .
As a result, the COVID-19 status of cancer patients is generally not evaluated at the beginning and/or in the course of their medical treatment. Additionally, the vast majority of cancer patients receive therapy on an out-patients basis; thus, asymptomatic COVID-19 positive patients are generally free to access the Oncology Units, representing a major Figure 1 ). Two subsequent swabs tested negative on April 3 and 4 for SARS-CoV-2 infection ( Figure 1) ; thus, the patient was considered cured from COVID-19 and she will resume ICI-therapy shortly.
These two cases are representative of potential clinical scenarios with whom oncologists can be faced in their daily practice due to the COVID-19 pandemic.
Undoubtedly, no general conclusion can be drawn from the positive outcome of these two patients on the reciprocal interplay between ICI therapy and SARS-CoV-2 infection.
Nevertheless, these findings seem to suggest that treatment with ICI is a doable approach during the COVID-19 pandemic, and that SARS-CoV-2 infection does not seem to represent an obstacle to grant cancer patients the best treatment according to their clinical setting. 